Skip to content

Medical emergency? What to do

FDA steps up action on misleading drug ads

3-RXPublished September 20, 20052 min read

Key points

  • Food and Drug Administration warnings to drug companies over misleading advertisements have more than tripled in the last year, an agency official said on Monday.
  • While the increase shows that agency staffers are better able to monitor materials, Abrams said, it also signals that companies are not doing enough to present balanced information.
  • Many offending ads either left out certain serious risks, while others used very small font size to mention them at the bottom of the page.
  • About half the letters also warned companies for making false claims about how well the drug worked, while about 40 percent cited them for wrongly comparing the featured drug to a competitor, he added.

U.S. Food and Drug Administration warnings to drug companies over misleading advertisements have more than tripled in the last year, an agency official said on Monday.

The agency sent 17 warning letters in the 12 months ending in August compared with an average of about four to five letters in recent years, Thomas Abrams, head of FDA's Division of Drug Marketing and Communications, told food and drug regulatory lawyers at a conference in Washington.

While the increase shows that agency staffers are better able to monitor materials, Abrams said, it also signals that companies are not doing enough to present balanced information.

The majority of the 17 letters, about 82 percent, cited companies for not including information about side effects and other risks in promotional materials for patients or doctors.

Many offending ads either left out certain serious risks, while others used very small font size to mention them at the bottom of the page.

"Industry can make efforts to better present risk information," Abrams said. "This is critical to public health."

About half the letters also warned companies for making false claims about how well the drug worked, while about 40 percent cited them for wrongly comparing the featured drug to a competitor, he added.

Abrams said drugmakers should do more to more to comply with advertising rules, and should present possible problems just as clearly as the drug's benefits.

"We are continuing to take necessary actions to ensure that prescription drug promotions have risk information," he said, adding that companies should voluntarily comply with standards.

Several guidelines about how to format promotions should be issued by the end of the year, he added.

Glenn Byrd, head of advertising for FDA's biological drug quality office, said letters involving makers of vaccines, blood products and other similar therapies also rose.

His office sent eight warning letters last year to various biological drug makers, including MedImmune Inc. and Ovation Pharmaceuticals, Inc, he said.

From August 2003 to August 2004, the biological drugs division sent five warning letters, according to the FDA Web site.

Byrd also said the agency was developing a Web site for consumers to follow advertising issues that should be online in 2006.

An FDA representative for devices, Deborah Wolf, said she did not know how many warnings the agency sent to manufacturers in the last year.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.